Regenera Activa introduces an innovative approach to regenerative treatment for AGA with our patented
medical device, engineered to obtain an injectable autologous micrograft solution called AMT® Triad.
This solution is composed of Progenitor cells, Human Smart Exosomes, and
Extracellular Matrix. It is
obtained from the patient’s mastoid area, a healthy biological tissue free of DHT.
Utilizing a mechanical disaggregation process, the biopsies are transformed into a solution that is
then injected into areas with impaired or damaged tissue.
The entire procedure, including biopsies obtention, disaggregation and ingrafting, takes
approximately 30 minutes.